Loading
A phase 1/2 trial of Capecitabine in colorectal cancer, run by BeyondBio Inc., now recruiting.
A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer is a phase 1/2 interventional study registered as NCT05093907 by BeyondBio Inc., with 27 participants planned, started 2021-08-31 and due to reach its primary completion in 2026-11-30. Interventions recorded: BEY1107, Capecitabine. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/